Switzerland's Oculis Q3 net loss widens as expenses rise

Overview

• Switzerland biopharma firm posted Q3 net loss as operating expenses rose yr/yr

• Company ended Q3 with $252 mln in cash and equivalents, runway into 2H 2029

• Completed patient randomization in Licaminlimab trial; Privosegtor trial enrollment ongoing

Outlook

• Oculis expects topline results from the Licaminlimab PREDICT-1 trial around year-end 2026

• Company anticipates IND clearance to initiate Privosegtor trials in acute MS relapses in Q4 2026

• Oculis says cash runway extends into 2H 2029

Result Drivers

• PIPELINE PROGRESS - Co cited completion of patient randomization in Licaminlimab PREDICT-1 trial and ongoing Privosegtor PIONEER-1 enrollment as key milestones

• OPERATING EXPENSES - Higher operating expenses driven by increased headcount-related costs and non-recurring corporate initiatives

• BIOMARKER DATA - New biomarker findings from Privosegtor Phase 2 ACUITY study supported its neuroprotective potential

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 11 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy."

• Wall Street's median 12-month price target for Oculis Holding AG is $39.00, about 405.8% above its November 2 closing price of $7.71

Reuters Recommended Reads

• Nov 2 - Switzerland's CRISPR Therapeutics Q3 CASGEVY revenue jumps 30% sequentially

• Nov 3 - Beam Therapeutics posts wider than expected Q3 net loss as revenue drops

• Nov 2 - Recursion Pharmaceuticals Q3 net loss narrows more than expected on lower costs

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)